Search Results - Sven Francque

Refine Results
  1. 1
    Pharmacological Treatment for Non-alcoholic Fatty Liver Disease

    Pharmacological Treatment for Non-alcoholic Fatty Liver Disease by Sven Francque, Luisa Vonghia

    Published 2019
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Immunological Mechanisms in the Pathophysiology of Non-Alcoholic Steatohepatitis

    Immunological Mechanisms in the Pathophysiology of Non-Alcoholic Steatohepatitis by Luisa Vonghia, P. Michielsen, Sven Francque

    Published 2013
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Treating NASH by targeting peroxisome proliferator-activated receptors

    Treating NASH by targeting peroxisome proliferator-activated receptors by Bart Staels, Laura Butruille, Sven Francque

    Published 2023
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Animal Models of Nonalcoholic Fatty Liver Disease—A Starter’s Guide

    Animal Models of Nonalcoholic Fatty Liver Disease—A Starter’s Guide by Mikhaïl Van Herck, Luisa Vonghia, Sven Francque

    Published 2017
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Breakthroughs in therapies for NASH and remaining challenges

    Breakthroughs in therapies for NASH and remaining challenges by Vlad Ratziu, Sven Francque, Arun J. Sanyal

    Published 2022
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    Therapeutic management of metabolic dysfunction associated steatotic liver disease

    Therapeutic management of metabolic dysfunction associated steatotic liver disease by Jing Zeng, Jian‐Gao Fan, Sven Francque

    Published 2024
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    Emerging role of ferroptosis in metabolic dysfunction-associated steatotic liver disease: revisiting hepatic lipid peroxidation

    Emerging role of ferroptosis in metabolic dysfunction-associated steatotic liver disease: revisiting hepatic lipid peroxidation by Cédric Peleman, Sven Francque, Tom Vanden Berghe

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Viral hepatitis and hepatocellular carcinoma.

    Viral hepatitis and hepatocellular carcinoma. by P. Michielsen, Sven Francque, Jurgen L van Dongen

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications

    Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications by Sven Francque, Denise van der Graaff, Wilhelmus J. Kwanten

    Published 2016
    Get full text
    Revisão
    Save to List
    Saved in:
  10. 10
    A turning point in hepatology? EASL reflects on the first approved drug for MASH

    A turning point in hepatology? EASL reflects on the first approved drug for MASH by Sven Francque, Aleksander Krag, Debbie L. Shawcross, Shira Zelber‐Sagi

    Published 2024
    Get full text
    Editorial
    Save to List
    Saved in:
  11. 11
    Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment

    Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment by Leen Heyens, Dana Busschots, Ger H. Koek, Geert Robaeys, Sven Francque

    Published 2021
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  12. 12
    Insights into the results of Resmetirom trials: Can a thyroid hormone receptor agonist be the holy grail of MASH therapy?

    Insights into the results of Resmetirom trials: Can a thyroid hormone receptor agonist be the holy grail of MASH therapy? by Konstantinos Arvanitakis, Theocharis Koufakis, Εvangelos Cholongitas, Sven Francque, Georgios Germanidis

    Published 2025
    Get full text
    Revisão
    Save to List
    Saved in:
  13. 13
    Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features

    Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features by Luisa Vonghia, Thea Magrone, An Verrijken, P. Michielsen, Luc Van Gaal, Emilio Jirillo, Sven Francque

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature

    Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature by Jeffrey V. Lazarus, Philip N. Newsome, Sven Francque, Fasiha Kanwal, Norah A. Terrault, Mary E. Rinella

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients

    Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients by Sven Francque, An Verrijken, Ilse Mertens, Guy Hubens, Eric Van Marck, Paul Pelckmans, P. Michielsen, Luc Van Gaal

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Future remnant liver function estimated by combining liver volumetry on magnetic resonance imaging with total liver function on 99m Tc-mebrofenin hepatobiliary scintigraphy: can this tool predict post-hepatectomy liver failure?

    Future remnant liver function estimated by combining liver volumetry on magnetic resonance imaging with total liver function on 99m Tc-mebrofenin hepatobiliary scintigraphy: can th... by T. Chapelle, Bart Op de Beeck, Ivan Huyghe, Sven Francque, Ann Driessen, Geert Roeyen, Dirk Ysebaert, Kathleen De Greef

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction–associated steatohepatitis

    Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction–associated steatohepatitis by Sven Francque, Alexander Hodge, Jérôme Boursier, Ziad Younes, Gerardo Rodriguez‐Araujo, Grace S. Park, Naim Alkhouri, Manal F. Abdelmalek

    Published 2024
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity

    The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity by Mikhaïl A. Van Herck, Jonas Weyler, Wilhelmus J. Kwanten, Eveline Dirinck, Benedicte Y. De Winter, Sven Francque, Luisa Vonghia

    Published 2019
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  19. 19
    Metabolic dysfunction-associated steatotic liver disease and the heart

    Metabolic dysfunction-associated steatotic liver disease and the heart by Stan Driessen, Sven Francque, Stefan D. Anker, Manuel Castro Cabezas, Diederick E. Grobbee, Maarten E. Tushuizen, Adriaan G. Holleboom

    Published 2023
    Get full text
    Revisão
    Save to List
    Saved in:
  20. 20
    Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trials

    Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trials by Jeanne Fichez, Thomas Mouillot, Luisa Vonghia, Charlotte Costentin, C Moreau, Marine Roux, Adèle Delamarre, Sven Francque, Ming‐Hua Zheng, Jérôme Boursier

    Published 2025
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: